Robert Glazer

4.2k total citations · 1 hit paper
50 papers, 3.3k citations indexed

About

Robert Glazer is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Robert Glazer has authored 50 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Cardiology and Cardiovascular Medicine, 13 papers in Surgery and 8 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Robert Glazer's work include Blood Pressure and Hypertension Studies (26 papers), Heart Failure Treatment and Management (21 papers) and Heart Rate Variability and Autonomic Control (12 papers). Robert Glazer is often cited by papers focused on Blood Pressure and Hypertension Studies (26 papers), Heart Failure Treatment and Management (21 papers) and Heart Rate Variability and Autonomic Control (12 papers). Robert Glazer collaborates with scholars based in United States, Switzerland and Italy. Robert Glazer's co-authors include Jay N. Cohn, Roberto Latini, Inder S. Anand, Serge Masson, Aldo P. Maggioni, Gianni Tognoni, Allen Hester, YannTong Chiang, Lloyd D. Fisher and Joseph Yen and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and Hypertension.

In The Last Decade

Robert Glazer

48 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT)

2003 661 citations Inder S. Anand, Lloyd D. Fisher et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert Glazer United States	26	2.9k	652	533	229	192	50	3.3k
Allen Hester United States	19	2.6k 0.9×	949 1.5×	483 0.9×	166 0.7×	232 1.2×	26	3.1k
Steffan Ekman Switzerland	11	2.6k 0.9×	1.2k 1.9×	728 1.4×	93 0.4×	301 1.6×	15	3.1k
Ingrid Copland Canada	7	2.5k 0.9×	394 0.6×	1.2k 2.3×	141 0.6×	178 0.9×	8	2.8k
Jay M. Sullivan United States	23	1.5k 0.5×	822 1.3×	491 0.9×	242 1.1×	98 0.5×	72	2.8k
Gary Peters United States	27	2.1k 0.7×	224 0.3×	925 1.7×	108 0.5×	290 1.5×	67	3.4k
Kasper Rossing Denmark	31	1.6k 0.6×	1.6k 2.4×	448 0.8×	456 2.0×	239 1.2×	89	4.1k
Patricia R. Hebert United States	23	1.4k 0.5×	499 0.8×	900 1.7×	379 1.7×	232 1.2×	49	3.0k
Leanne Dyal Canada	15	1.9k 0.7×	1.3k 2.0×	659 1.2×	388 1.7×	264 1.4×	24	3.2k
Rita Paniccia Italy	34	3.1k 1.1×	515 0.8×	1.5k 2.7×	333 1.5×	559 2.9×	100	4.4k
Ettore Ambrosioni Italy	28	2.6k 0.9×	654 1.0×	448 0.8×	189 0.8×	128 0.7×	117	3.2k

Countries citing papers authored by Robert Glazer

Since Specialization

Citations

This map shows the geographic impact of Robert Glazer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Glazer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Glazer more than expected).

Fields of papers citing papers by Robert Glazer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Glazer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Glazer. The network helps show where Robert Glazer may publish in the future.

Co-authorship network of co-authors of Robert Glazer

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Glazer. A scholar is included among the top collaborators of Robert Glazer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Glazer. Robert Glazer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stiller, Brigitte, Hui‐Kim Yap, Hee Gyung Kang, et al.. (2018). Long-term safety and tolerability of valsartan in children aged 6 to 17 years with hypertension. Pediatric Nephrology. 34(3). 495–506. 9 indexed citations

Philipp, Thomas, Robert Glazer, Margaret Wernsing, & Joseph Yen. (2011). Initial combination therapy with amlodipine/valsartan compared with monotherapy in the treatment of hypertension. Journal of the American Society of Hypertension. 5(5). 417–424. 9 indexed citations

Lacourcière, Yves, et al.. (2011). 24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension. Journal of Human Hypertension. 25(10). 615–622. 30 indexed citations

Smith, Timothy R., et al.. (2010). Combination therapy with amlodipine/valsartan in essential hypertension: a 52-week, randomised, open-label, extension study. International Journal of Clinical Practice. 64(10). 1367–1374. 11 indexed citations

Weinberger, M H, et al.. (2010). Achieving blood pressure goal: initial therapy with valsartan/hydrochlorothiazide combination compared with monotherapy. Journal of Human Hypertension. 24(12). 823–830. 7 indexed citations

Pool, James L., et al.. (2009). The Role of Baseline Blood Pressure in Guiding Treatment Choice. Clinical Drug Investigation. 29(12). 791–802. 4 indexed citations

Levy, Daniel, et al.. (2007). Time to Achieve Blood-Pressure Goal: Influence of Dose of Valsartan Monotherapy and Valsartan and Hydrochlorothiazide Combination Therapy. American Journal of Hypertension. 20(7). 807–815. 42 indexed citations

Philipp, Thomas, Timothy R. Smith, Robert Glazer, et al.. (2007). Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clinical Therapeutics. 29(4). 563–580. 212 indexed citations

Pool, James L., et al.. (2007). Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: A double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clinical Therapeutics. 29(1). 61–73. 72 indexed citations

10.

Krum, Henry, Roberto Latini, Aldo P. Maggioni, et al.. (2006). Statins and symptomatic chronic systolic heart failure: A post-hoc analysis of 5010 patients enrolled in Val-HeFT. International Journal of Cardiology. 119(1). 48–53. 50 indexed citations

11.

Wong, Maylene, Lidia Staszewsky, Elisa Carretta, et al.. (2005). Signs and Symptoms in Chronic Heart Failure: Relevance of Clinical Trial Results to Point of Care—Data from Val-HeFT. European Journal of Heart Failure. 8(5). 502–508. 9 indexed citations

12.

Majani, Giuseppina, Anna Giardini, Cristina Opasich, et al.. (2005). Effect of Valsartan on Quality of Life When Added to Usual Therapy for Heart Failure: Results From The Valsartan Heart Failure Trial. Journal of Cardiac Failure. 11(4). 253–259. 45 indexed citations

13.

Krum, Henry, Peter E. Carson, Csaba Farsang, et al.. (2004). Effect of Valsartan Added to Background ACE Inhibitor Therapy in Patients with Heart Failure: Results from Val-HeFT. European Journal of Heart Failure. 6(7). 937–945. 70 indexed citations

14.

Anand, Inder S., Joseph Yen, Viorel G. Florea, et al.. (2004). 1163-121 Prognostic role of neutrophil and lymphocyte counts in heart failure: Results from Val-HeFT. Journal of the American College of Cardiology. 43(5). A229–A229. 1 indexed citations

15.

Wong, Maylene, Lidia Staszewsky, Roberto Latini, et al.. (2004). Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure. Journal of the American College of Cardiology. 43(11). 2022–2027. 172 indexed citations

16.

Anand, Inder S., Roberto Latini, Serge Masson, et al.. (2004). 1163-114 Prognostic role of plasma C-reactive protein in heart failure: Results from Val-HeFT. Journal of the American College of Cardiology. 43(5). A227–A227.

17.

Anand, Inder S., Lloyd D. Fisher, Roberto Latini, et al.. (2003). Changes in plasma brain natriuretic peptide and norepinephrine over time and subsequent mortality and morbidity in heart failure: Results from Val-HeFT. Journal of the American College of Cardiology. 41(6). 222–222. 1 indexed citations

18.

Cohn, Jay N., Gianni Tognoni, Robert Glazer, Dirk Spormann, & Allen Hester. (1999). Rationale and design of the valsartan heart failure trial: A large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. Journal of Cardiac Failure. 5(2). 155–160. 116 indexed citations

19.

Glazer, Robert, et al.. (1999). Dose-response efficacy of valsartan, a new angiotensin II receptor blocker. Journal of Human Hypertension. 13(4). 275–281. 49 indexed citations

20.

Acuña, Enzo, et al.. (1996). Treatment of patients with essential hypertension: amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo. Clinical Therapeutics. 18(6). 1213–1224. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact